Literature DB >> 11884127

The methyl group of N(alpha)(Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage.

Rainer Friedrich1, Torsten Steinmetzer, Robert Huber, Jörg Stürzebecher, Wolfram Bode.   

Abstract

Bivalent peptidic thrombin inhibitors consisting of an N-terminal d-cyclohexylalanine-Pro-N(alpha)(Me)Arg active-site fragment, a flexible polyglycine linker, and a C-terminal hirugen-like segment directed towards the fibrinogen recognition exosite inhibit thrombin with K(i) values in the picomolar range, remaining stable in buffered solution at pH 7.8 for at least 15 hours. In order to investigate the structural basis of this increased stability, the most potent of these inhibitors, I-11 (K(i)=37pM), containing an N(alpha)(Me)Arg-Thr bond, was crystallized in complex with human alpha-thrombin. X-ray data were collected to 1.8A resolution and the crystal structure of this complex was determined. The Fourier map displays clear electron density for the N-terminal fragment and for the exosite binding segment. It indicates, however, that in agreement with Edman sequencing, the peptide had been cleaved in the crystal, presumably due to the long incubation time of 14 days needed for crystallization and data collection. The N(alpha)(Me) group is directed toward the carbonyl oxygen atom of Ser214, pushing the Ser195 O(gamma) atom out of its normal site. This structure suggests that upon thrombin binding, the scissile peptide bond of the intact peptide and the Ser195 O(gamma) are separated from each other, impairing the nucleophilic attack of the Ser195 O(gamma) toward the N(alpha)(Me)Arg carbonyl group. In the time-scale of two weeks, however, cleavage geometries favoured by the crystal allow catalysis at a slow rate. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884127     DOI: 10.1006/jmbi.2001.5394

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  8 in total

Review 1.  The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.

Authors:  Toni M Antalis; Marguerite S Buzza; Kathryn M Hodge; John D Hooper; Sarah Netzel-Arnett
Journal:  Biochem J       Date:  2010-06-15       Impact factor: 3.857

Review 2.  Emerging principles in protease-based drug discovery.

Authors:  Marcin Drag; Guy S Salvesen
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

3.  Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.

Authors:  Rajeev Goswami; Subhendu Mukherjee; Gerd Wohlfahrt; Chakshusmathi Ghadiyaram; Jwala Nagaraj; Beeram Ravi Chandra; Ramesh K Sistla; Leena K Satyam; Dodheri S Samiulla; Anu Moilanen; Hosahalli S Subramanya; Murali Ramachandra
Journal:  ACS Med Chem Lett       Date:  2013-10-07       Impact factor: 4.345

4.  Structural basis of an epitope tagging system derived from Haloarcula marismortui bacteriorhodopsin I D94N and its monoclonal antibody GD-26.

Authors:  Po-Jung Pao; Min-Feng Hsu; Ming-Hui Chiang; Chun-Ting Chen; Cheng-Chung Lee; Andrew H-J Wang
Journal:  FEBS J       Date:  2021-10-01       Impact factor: 5.622

5.  Proton bridging in the interactions of thrombin with hirudin and its mimics.

Authors:  Ildiko M Kovach; Lazaros Kakalis; Frank Jordan; Daoning Zhang
Journal:  Biochemistry       Date:  2013-04-01       Impact factor: 3.162

Review 6.  Proton Bridging in Catalysis by and Inhibition of Serine Proteases of the Blood Cascade System.

Authors:  Ildiko M Kovach
Journal:  Life (Basel)       Date:  2021-04-27

7.  Rational design and characterization of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors.

Authors:  Ana C Figueiredo; Cristina C Clement; Sheuli Zakia; Julian Gingold; Manfred Philipp; Pedro J B Pereira
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

8.  Visualization of Topological Pharmacophore Space with Graph Edit Distance.

Authors:  Hiroshi Nakano; Tomoyuki Miyao
Journal:  ACS Omega       Date:  2022-04-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.